ASCO 2011

 
 
 

47th Annual Meeting of the American Society of Clinical Oncology.

 

Consider adding rituximab in treatment of DLBCL

Mark Fuerst Read Article
Published: 06/22/11

DLBCL.jpg

First-line therapy with rituximab plus conventional chemotherapy for 8 courses could be regarded a standard of care for young, CD20+ diffuse large B-cell lymphoma (DLBCL) patients who respond to 4 courses of therapy, accoring to Jean Noel Milpied, MD, of the Hospital Haut-Leveque, Pessac, France, who presented at the American Society of Clinical Oncology annual meeting held in Chicago, June 4-8  [Read Article]

Adding rituximab improves EFS in B-cell lymphoma

Mark Fuerst Read Article
Published: 06/21/11

800px-Rituximab.png
Rituximab

The addition of only 6 infusions of rituximab to 8 cycles of conventional chemotherapy can improve event-free survival (EFS) for young, high-risk patients with aggressive B-cell lymphoma. A number of prospective, randomized trials have tested high-dose therapy (HDT) followed by autologous stem cell transplantation as part of conventional first-line therapy for younger patients with aggressive B-cell lymphoma. “The real problem is that none of these studies used rituximab,” said Norbert Schmitz, MD of Asklepios Klinik St. George Hamburg, Germany, at the American Society of Clinical Oncology annual meeting in Chicago. [Read Article]

Autotransplant after induction in aggressive NHL

Mark Fuerst Read Article
Published: 06/20/11

stemcells.jpg

Autologous stem cell transplantation appears to improve progression-free survival (PFS) for patients with high-intermediate (H-Int) or high International Prognostic Index (IPI) risk diffuse aggressive non-Hodgkin’s lymphoma (NHL) with objective responses to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)–based induction therapy, according to Patrick Stiff, MD, of Loyola University Medical Center, who presented the findings at the American Society of Clinical Oncology annual meeting in Chicago. [Read Article]

R-CHOP14 not superior to standard R-CHOP21 in DLBCL

Mark Fuerst Read Article
Published: 06/17/11

diffuse_large_bcell_lymphoma_cd20.jpg

Treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP 14) administered every 14 days does not improve overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma (DLBC NHL) compared with standard 21-day treatment (R-CHOP 21), according to David Cunningham, MD, who spoke at the American Society of Clinical Oncology in Chicago. [Read Article]

Deeper molecular responses to nilotinib protect CML patients

Mark Fuerst Read Article
Published: 06/14/11

CML.jpg

Deeper molecular responses with nilotinib protect chronic myeloid leukemia (CML) patients from the development of emerging mutations and progression to advanced disease. A recent trial of newly diagnosed Philadelphia-positive CML Patients (ENESTnd), nilotinib demonstrated superior efficacy and significantly reduced rates of progression to accelerated phase/blast crisis (AP/BC) over imatinib in patients. The findings were presented at the American Society of Clinical Oncology annual meeting in Chicago. [Read Article]

JAK inhibitor ruxolitinib improves treatment landscape in MF

Mark Fuerst Read Article
Published: 06/11/11

Splenomegaly_Courtesy S. Verstovsek.jpg
Splenomegaly

Two phase 3 studies demonstrate the effectiveness of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in treating patients with myelofibrosis (MF), according to presentations at the 2011 ASCO Annual Meeting. Ruxolitinib has the potential to change the treatment landscape in MF, said Alessandro Vannucchi, MD, of the University of Florence, who reported the results of the COMFORT-II trial. Srdan Verostovsek, MD, PhD, of the MD Anderson Cancer Center, presented results from COMFORT-I. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}